Exponent Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Exponent ha aumentado sus beneficios a una tasa media anual de 2.2%, mientras que los beneficios de la industria de Professional Services han experimentado un crecimiento de 12.3% anual. Los ingresos han ido creciendo a una tasa media de 5.8% al año. La rentabilidad financiera de Exponent es de 32.2%, y sus márgenes netos son de 19.8%.
Información clave
2.24%
Tasa de crecimiento de los beneficios
2.99%
Tasa de crecimiento del BPA
| Crecimiento de la industria Professional Services | 10.99% |
| Tasa de crecimiento de los ingresos | 5.79% |
| Rentabilidad financiera | 32.20% |
| Margen neto | 19.76% |
| Última actualización de beneficios | 03 Apr 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • May 23
EXPO: Buybacks And Resilient End Markets Will Support Future Earnings Quality
Analysts have trimmed their fair value estimate for Exponent to $90 from $95, reflecting lower price targets in recent research and a stronger emphasis on selectivity in smaller cap industrials. Analyst Commentary Recent research points to a more selective stance on smaller cap industrials, with Exponent still viewed as a quality exposure for investors who prioritize resilient demand and clear growth drivers.Seeking Alpha • May 04
Exponent: Rising Demand And A Reasonable Valuation Make It A Buy
Summary Exponent is a market leader in scientific and engineering consulting, boasting a 13-year dividend growth streak and a fortress balance sheet. EXPO’s fiscal 2026 outlook signals rising top and bottom lines, with AI-related demand driving proactive and reactive service growth. The stock trades at ~26.5x FY26E EPS, well below its 5-year average, suggesting undervaluation with a fair value estimate of $73.80 versus a ~$65 share price. Dividend safety is outstanding, supported by a conservative ~50% payout ratio, robust free cash flow, and no debt. Read the full article on Seeking AlphaActualización de narrativa • May 03
EXPO: AI Failure Analysis And Buybacks Will Support Higher Earnings Quality
Analysts have adjusted their view on Exponent with a modest change to the price target in the $5 range, reflecting updated assumptions on growth, profitability and a slightly higher future P/E multiple informed by recent mixed revisions from JPMorgan and UBS. Analyst Commentary Recent commentary around Exponent highlights a mix of caution and optimism, with price targets adjusted within a narrow range and opinions split on the risk and reward at current levels.Actualización de narrativa • Apr 18
EXPO: AI Failure Analysis Demand Will Support Higher Earnings Quality
Analysts have adjusted the 12 month price target on Exponent to $95 from $90, reflecting updated assumptions around revenue growth, profit margins, and the P/E multiple they are willing to apply to future earnings. Analyst Commentary Recent Street research on Exponent has centered on how much investors are willing to pay for the company’s future earnings, with price targets adjusted as analysts revisit revenue assumptions, profit margins, and the P/E multiple.
Actualización de narrativa • Apr 04
EXPO: AI Failure Analysis Work Will Sustain Premium P/E And Shareholder Returns
Analysts have trimmed their average price target for Exponent by $1.67 to reflect slightly lower fair value and profit margin assumptions, while still applying a relatively high future P/E multiple informed by recent mixed price target moves from JPMorgan and UBS. Analyst Commentary Recent Street research on Exponent reflects a mix of optimism about the business model and caution around valuation and near term execution, which is why price targets have moved in both directions.Actualización de narrativa • Mar 21
EXPO: AI Failure Analysis Work Will Support Margins And Shareholder Returns
Analysts have lifted their 12 month price target on Exponent by about $6 to around $92. This reflects updated expectations around revenue, margins and a slightly lower future P/E multiple following recent research updates from major firms.
Actualización de narrativa • Mar 07
EXPO: Buybacks And Dividend Increases Will Support Future Shareholder Returns
Analysts nudged their price target on Exponent higher by $4, citing slightly firmer growth and margin assumptions, along with a modestly lower future P/E outlook as key supports for the revised view. Analyst Commentary Recent research coverage around Exponent has centered on how much investors should be willing to pay for the company relative to its growth and margin profile.Actualización de narrativa • Feb 20
EXPO: Raised UBS Target And Buybacks Will Support Higher Future P/E
Analysts have raised their price target on Exponent by $4 to $85, citing updated assumptions that include slightly lower revenue growth, a modestly higher discount rate, improved profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent Street research around Exponent highlights a mix of optimism and restraint, with the latest published work focusing on valuation inputs, growth expectations, and how much investors are willing to pay for the stock through the P/E multiple.Artículo de análisis • Feb 09
Exponent (NASDAQ:EXPO) Is Increasing Its Dividend To $0.31
The board of Exponent, Inc. ( NASDAQ:EXPO ) has announced that the dividend on 20th of March will be increased to...Actualización de narrativa • Feb 06
EXPO: Bullish JPMorgan Initiation Will Support Confidence In Updated Fair Value Estimate
Analysts have raised their fair value estimate for Exponent from US$76.00 to US$81.00, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple in light of recent bullish Street research. Analyst Commentary Recent Street research, including a new bullish view from JPMorgan, has put more attention on how Exponent is priced and what could get in the way of the updated fair value estimate of US$81.00.Actualización de narrativa • Jan 23
EXPO: AI Failure Analysis Work Will Offset Automation Headwind Risks
Analysts have trimmed their price target on Exponent to US$90 from US$100, citing both the potential for increased AI driven failure analysis work and the offsetting risk that greater automation could reduce billable hours in consulting. Analyst Commentary Recent research points to a more balanced view on Exponent, with the reduced US$90 price target reflecting both potential upside from AI driven work and execution risks around automation in core consulting practices.Actualización de narrativa • Jan 09
EXPO: AI Failure Analysis Demand Will Support Future Consulting Engagements
Analysts have reduced their fair value estimate for Exponent to $90 from $100, citing a lower assumed future P/E multiple as they weigh the potential for AI-driven demand for failure analysis work against the risk that automation could reduce billable hours across the consulting sector. Analyst Commentary Recent commentary from bullish analysts centers on how AI adoption could shape Exponent's long term opportunity set, even as they factor in the risk that automation may cap billable hours across the consulting sector.Artículo de análisis • Jan 08
What Exponent, Inc.'s (NASDAQ:EXPO) P/E Is Not Telling You
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 34.9x might make it look like a strong sell...Actualización de narrativa • Dec 16
EXPO: AI Failure Analysis Demand Will Outweigh Automation Efficiency Headwinds
Analysts have nudged their fair value estimate for Exponent higher to approximately $85.50 from $83.00 per share, citing the potential for AI driven demand in complex failure analysis work, while acknowledging that automation related efficiency gains could temper billable hours across the consulting industry. Analyst Commentary Bullish analysts highlight that the revised target still implies meaningful upside from current levels, even after a modest trim.Actualización de narrativa • Dec 01
EXPO: AI-Driven Demand Will Drive Future Engagements Despite Automation Headwinds
Analysts have revised Exponent's price target downward by $10 to $90 per share, citing potential opportunities from AI-driven engagements as well as industry headwinds related to automation efficiencies. Analyst Commentary Following the recent revision to Exponent's price target, analysts have highlighted both opportunities and risks facing the company in today's evolving market landscape.Actualización de narrativa • Nov 17
EXPO: AI-Driven Client Demand Will Offset Automation Concerns In Consulting
Exponent’s analyst price target has been reduced by $10 to $90, as analysts cite ongoing automation concerns that could impact the consulting sector. They also note potential opportunities from increased AI-driven client demand.Artículo de análisis • Nov 02
Exponent, Inc. Just Beat EPS By 8.5%: Here's What Analysts Think Will Happen Next
A week ago, Exponent, Inc. ( NASDAQ:EXPO ) came out with a strong set of third-quarter numbers that could potentially...Actualización de narrativa • Nov 02
EXPO: Increased Buyback Will Drive Shareholder Returns In Coming Quarters
Narrative Update: Exponent Analyst Price Target Adjustment Analysts have lowered their price target for Exponent from $88 to $83. This change reflects updated expectations for revenue growth and profitability margins moving forward.Artículo de análisis • Oct 06
Returns On Capital At Exponent (NASDAQ:EXPO) Have Stalled
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Artículo de análisis • Jul 30
A Look At The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$63.97 based on 2 Stage Free Cash Flow to Equity Exponent's US$70.44...Artículo de análisis • Jul 14
When Should You Buy Exponent, Inc. (NASDAQ:EXPO)?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it received a lot of attention from a substantial...Artículo de análisis • Jun 28
Exponent (NASDAQ:EXPO) Knows How To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Artículo de análisis • May 27
Subdued Growth No Barrier To Exponent, Inc.'s (NASDAQ:EXPO) Price
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 36.7x might make it look like a strong sell...Artículo de análisis • Apr 06
Is Exponent, Inc. (NASDAQ:EXPO) Potentially Undervalued?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it saw significant share price movement during...Artículo de análisis • Mar 22
Return Trends At Exponent (NASDAQ:EXPO) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Mar 10
Exponent: A Unique Dividend Contender That Is Valued At A Premium
Summary Exponent Inc. is a market leader in scientific and engineering consulting, with a 13-year dividend growth streak and a solid balance sheet. Despite strong revenue and earnings growth, the valuation is at a premium, making Exponent a hold. The company's competitive advantages include its reputation, technical expertise, and long-term client relationships, ensuring continued market leadership. Exponent's dividend safety is excellent, supported by a conservative payout ratio and robust free cash flow, but the current valuation is a concern. Read the full article on Seeking AlphaArtículo de análisis • Feb 13
Exponent's (NASDAQ:EXPO) Shareholders Will Receive A Bigger Dividend Than Last Year
Exponent, Inc.'s ( NASDAQ:EXPO ) dividend will be increasing from last year's payment of the same period to $0.30 on...Artículo de análisis • Jan 30
Exponent, Inc.'s (NASDAQ:EXPO) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights The projected fair value for Exponent is US$122 based on 2 Stage Free Cash Flow to Equity Exponent is...Artículo de análisis • Dec 28
Risks To Shareholder Returns Are Elevated At These Prices For Exponent, Inc. (NASDAQ:EXPO)
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 42.7x might make it look like a strong sell...Artículo de análisis • Dec 10
Here's What To Make Of Exponent's (NASDAQ:EXPO) Decelerating Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Artículo de análisis • Nov 08
Exponent's (NASDAQ:EXPO) Earnings Seem To Be Promising
Despite posting healthy earnings, Exponent, Inc.'s ( NASDAQ:EXPO ) stock has been quite weak. Along with the solid...Artículo de análisis • Oct 13
Estimating The Intrinsic Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$114 based on 2 Stage Free Cash Flow to Equity Current share price of...
Nueva narrativa • Aug 29
Operational Efficiency And Tactical Investments Set To Propel Future Profitability And Revenue Growth
Exponent's strategic management and operational efficiency improvements are poised to enhance future profitability and earnings potential.Artículo de análisis • Aug 20
Exponent, Inc.'s (NASDAQ:EXPO) Share Price Not Quite Adding Up
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 51.1x might make it look like a strong sell...Artículo de análisis • Jul 28
Exponent, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, Exponent, Inc. ( NASDAQ:EXPO ) recently reported its second-quarter numbers. Revenues were US$132m...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Exponent. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 03 Apr 26 | 551 | 109 | 42 | 0 |
| 02 Jan 26 | 537 | 106 | 41 | 0 |
| 03 Oct 25 | 531 | 105 | 40 | 0 |
| 04 Jul 25 | 519 | 103 | 38 | 0 |
| 04 Apr 25 | 519 | 106 | 37 | 0 |
| 03 Jan 25 | 518 | 109 | 37 | 0 |
| 27 Sep 24 | 509 | 106 | 36 | 0 |
| 28 Jun 24 | 508 | 105 | 35 | 0 |
| 29 Mar 24 | 506 | 101 | 35 | 0 |
| 29 Dec 23 | 497 | 100 | 35 | 0 |
| 29 Sep 23 | 496 | 102 | 36 | 0 |
| 30 Jun 23 | 486 | 102 | 36 | 0 |
| 31 Mar 23 | 475 | 102 | 34 | 0 |
| 30 Dec 22 | 464 | 102 | 33 | 0 |
| 30 Sep 22 | 456 | 100 | 31 | 0 |
| 01 Jul 22 | 449 | 100 | 28 | 0 |
| 01 Apr 22 | 443 | 100 | 25 | 0 |
| 31 Dec 21 | 435 | 101 | 24 | 0 |
| 01 Oct 21 | 428 | 103 | 20 | 0 |
| 02 Jul 21 | 413 | 96 | 19 | 0 |
| 02 Apr 21 | 388 | 87 | 19 | 0 |
| 01 Jan 21 | 378 | 83 | 22 | 0 |
| 02 Oct 20 | 383 | 80 | 25 | 0 |
| 03 Jul 20 | 385 | 81 | 28 | 0 |
| 03 Apr 20 | 398 | 86 | 31 | 0 |
| 03 Jan 20 | 391 | 82 | 30 | 0 |
| 27 Sep 19 | 374 | 79 | 27 | 0 |
| 28 Jun 19 | 368 | 77 | 24 | 0 |
| 29 Mar 19 | 357 | 75 | 20 | 0 |
| 28 Dec 18 | 355 | 72 | 18 | 0 |
| 28 Sep 18 | 352 | 53 | 24 | 0 |
| 29 Jun 18 | 346 | 50 | 24 | 0 |
| 30 Mar 18 | 340 | 45 | 24 | 0 |
| 29 Dec 17 | 330 | 41 | 18 | 0 |
| 29 Sep 17 | 320 | 55 | 26 | 0 |
| 30 Jun 17 | 312 | 52 | 25 | 0 |
| 31 Mar 17 | 301 | 49 | 24 | 0 |
| 30 Dec 16 | 299 | 47 | 22 | 0 |
| 30 Sep 16 | 296 | 47 | 23 | 0 |
| 01 Jul 16 | 297 | 47 | 23 | 0 |
| 01 Apr 16 | 299 | 49 | 23 | 0 |
| 01 Jan 16 | 296 | 44 | 23 | 0 |
| 02 Oct 15 | 296 | 43 | 23 | 0 |
| 03 Jul 15 | 295 | 42 | 24 | 0 |
Ingresos de calidad: EXPO tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(19.8%) de EXPO son inferiores a los del año pasado (20.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de EXPO han crecido un 2.2% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de EXPO en el último año (3.2%) supera su media de 5 años (2.2% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de EXPO en el último año (3.2%) no superó al de la industria Professional Services 8.7%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (32.2%) de EXPO se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/26 23:20 |
| Precio de las acciones al final del día | 2026/05/26 00:00 |
| Beneficios | 2026/04/03 |
| Ingresos anuales | 2026/01/02 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Exponent, Inc. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joseph Foresi | Brean Capital Historical (Janney Montgomery) |
| Alexis Huseby | D.A. Davidson & Co. |
| Tomohiko Sano | J.P. Morgan |